BACKGROUND: Nonsurgical aesthetic treatment of the nose is becoming increasingly popular. VYC-25L is a novel hyaluronic acid product with the high G' and cohesivity required of a nasal filler.OBJECTIVES: To assess the safety and efficacy of VYC-25L for treatment of the nose using a previously published grid-based protocol.METHODS: This was a retrospective, single-center analysis of data from adult patients undergoing treatment of the nose with VYC-25L between February and April 2019, using the grid system as the reference for injection quantity and sequencing. Specific procedures included correction of inadequate projection, deep glabella treatment, correction of a nasal hump, and adjustment of the nasolabial angle and columella. Patients were followed up for 6-9 months.RESULTS: Sixty-one patients were included in the analysis (mean age, 32 ± 3 years; n=45 females [74%]). At 2 weeks post-treatment, a high degree of defect correction was confirmed based on independent evaluation, with all patients scoring 9 or 10 on a 10-point Visual Analog Scale. Fifty-nine of 61 patients (97%) self-assessed the degree of correction as 'adequate'. Results were stable at 3- and 6-month follow-up visits. Complications recorded were bruising (n=15, 25%), asymmetry (n=2, 3%), and hematoma (n=1, 2%). All resolved rapidly. There were no cases of infection, bumps, or skin necrosis.CONCLUSIONS: VYC-25L is safe and efficacious for treatment of the nose, with high levels of patient satisfaction. It has potential to be a valuable tool in nonsurgical rhinoplasty.

Nonsurgical Rhinoplasty With the Novel Hyaluronic Acid Filler VYC-25L: Results Using a Nasal Grid Approach

Bertossi, Dario;Malchiodi, Luciano;Albanese, Massimo;Nocini, Riccardo;Nocini, Pier Francesco
2021-01-01

Abstract

BACKGROUND: Nonsurgical aesthetic treatment of the nose is becoming increasingly popular. VYC-25L is a novel hyaluronic acid product with the high G' and cohesivity required of a nasal filler.OBJECTIVES: To assess the safety and efficacy of VYC-25L for treatment of the nose using a previously published grid-based protocol.METHODS: This was a retrospective, single-center analysis of data from adult patients undergoing treatment of the nose with VYC-25L between February and April 2019, using the grid system as the reference for injection quantity and sequencing. Specific procedures included correction of inadequate projection, deep glabella treatment, correction of a nasal hump, and adjustment of the nasolabial angle and columella. Patients were followed up for 6-9 months.RESULTS: Sixty-one patients were included in the analysis (mean age, 32 ± 3 years; n=45 females [74%]). At 2 weeks post-treatment, a high degree of defect correction was confirmed based on independent evaluation, with all patients scoring 9 or 10 on a 10-point Visual Analog Scale. Fifty-nine of 61 patients (97%) self-assessed the degree of correction as 'adequate'. Results were stable at 3- and 6-month follow-up visits. Complications recorded were bruising (n=15, 25%), asymmetry (n=2, 3%), and hematoma (n=1, 2%). All resolved rapidly. There were no cases of infection, bumps, or skin necrosis.CONCLUSIONS: VYC-25L is safe and efficacious for treatment of the nose, with high levels of patient satisfaction. It has potential to be a valuable tool in nonsurgical rhinoplasty.
2021
N/A
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1027654
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact